Micro-computed tomography and nuclear magnetic resonance imaging for noninvasive, live-mouse cholangiography

Laboratory Investigation

Volumn 93, Issue 6, 2013, Pages 733-743

  Tabibian, James H ^a   MacUra, Slobodan I ^a   O'Hara, Steven P ^a   Fidler, Jeff L ^a   Glockner, James F ^a   Takahashi, Naoki ^a   Lowe, Val J ^a   Kemp, Bradley J ^a   Mishra, Prasanna K ^a   Tietz, Pamela S ^a   Splinter, Patrick L ^a   Trussoni, Christy E ^a   Larusso, Nicholas F ^a  

^a MAYO CLINIC   (United States)

Author keywords

animal models; biliary tract diseases; live animal imaging; magnetic resonance cholangiopancreatography; primary sclerosing cholangitis; strictures

Indexed keywords

ADIPIODONE; ADIPIODONE MEGLUMINE; GADOXETIC ACID; GLUCAGON; ISOFLURANE;

ANESTHESIA; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BILE DUCT LIGATION; CHOLANGIOGRAPHY; COMPUTED TOMOGRAPHY SCANNER; CONTROLLED STUDY; DISSECTION; DRUG DOSE ESCALATION; FEMALE; IN VIVO STUDY; LIVER HISTOLOGY; MALE; MICRO-COMPUTED TOMOGRAPHY; MOUSE; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PET SCANNER; PRIMARY SCLEROSING CHOLANGITIS; PRIORITY JOURNAL; SPECTROMETER; VALIDATION PROCESS;

EID: 84878583731     PISSN: 00236837     EISSN: 15300307     Source Type: Journal    
DOI: 10.1038/labinvest.2013.52     Document Type: Article

References (36)

1. Lazaridis KN, Strazzabosco M, Larusso NF. The cholangiopathies: disorders of biliary epithelia. Gastroenterology 2004;127:1565-1577.
2. Tabibian JH, Masyuk AI, Masyuk TV, LaRusso NF. Cholangiocyte Physiology. Comprehensive Physiology 2013;3:541-565.
3. Tabibian JH, O'Hara SP, Larusso NF. Primary sclerosing cholangitis: the gut-liver axis. Clin Gastroenterol Hepatol 2012;10:819.
4. Lindor KD. Ursodiol for primary sclerosing cholangitis. Mayo Primary Sclerosing Cholangitis-Ursodeoxycholic Acid Study Group. N Engl J Med 1997;336:691-695.
5. O'Hara SP, Tabibian JH, Splinter PL, et al. The dynamic biliary epithelia: molecules, pathways, and disease. J Hepatol 2012;58:575-582.
6. Boonstra K, Beuers U, Ponsioen CY. Epidemiology of primary sclerosing cholangitis and primary biliary cirrhosis: a systematic review. J Hepatol 2012;56:1181-1188.
7. Bambha K, Kim WR, Talwalkar J, et al. Incidence, clinical spectrum, and outcomes of primary sclerosing cholangitis in a United States community. Gastroenterology 2003;125:1364-1369.
8. Fickert P, Zollner G, Fuchsbichler A, et al. Ursodeoxycholic acid aggravates bile infarcts in bile duct-ligated and Mdr2 knockout mice via disruption of cholangioles. Gastroenterology 2002;123:1238-1251.
9. Pollheimer MJ, Trauner M, Fickert P. Will we ever model PSC? - ''it's hard to be a PSC model!''. Clin Res Hepatol Gastroenterol 2011;35: 792-804.
10. Tabibian JH, Lindor KD. Primary sclerosing cholangitis: a review and update on therapeutic developments. Expert Rev Gastroenterol Hepatol 2013;7:103-114.
11. Tabibian JH, Weeding E, Jorgensen RA, et al. Randomised clinical trial: vancomycin or metronidazole in patients with primary sclerosing cholangitis - a pilot study. Aliment Pharmacol Ther 2013;37:604-612.
12. Wiesner RH, LaRusso NF. Clinicopathologic features of the syndrome of primary sclerosing cholangitis. Gastroenterology 1980;79:200-206.
13. Vitellas KM, Keogan MT, Freed KS, et al. Radiologic manifestations of sclerosing cholangitis with emphasis on MR cholangiopancreatography. Radiographics 2000;20:959-975.
14. Chapman R, Fevery J, Kalloo A, et al. Diagnosis and management of primary sclerosing cholangitis. Hepatology 2010;51:660-678.
15. Fickert P, Fuchsbichler A, Wagner M, et al. Regurgitation of bile acids from leaky bile ducts causes sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2004;127:261-274.
16. Wallner BK, Schumacher KA, Weidenmaier W, et al. Dilated biliary tract: evaluation with MR cholangiography with a T2-weighted contrastenhanced fast sequence. Radiology 1991;181:805-808.
17. Dave M, Elmunzer BJ, Dwamena BA, et al. Primary sclerosing cholangitis: meta-analysis of diagnostic performance of MR cholangiopancreatography. Radiology 2010;256:387-396.
18. Tabibian JH, Lindor KD. Challenges of cholangiocarcinoma detection in patients with primary sclerosing cholangitis. J Analyt Oncol 2012;1:5.
19. Hirao K, Miyazaki A, Fujimoto T, et al. Evaluation of aberrant bile ducts before laparoscopic cholecystectomy: helical CT cholangiography versus MR cholangiography. Am J Roentgenol 2000;175: 713-720.
20. Fleischmann D, Ringl H, Schofl R, et al. Three-dimensional spiral CT cholangiography in patients with suspected obstructive biliary disease: comparison with endoscopic retrograde cholangiography. Radiology 1996;198:861-868.
21. Yeh BM, Breiman RS, Taouli B, et al. Biliary tract depiction in living potential liver donors: comparison of conventional MR, mangafodipir trisodium-enhanced excretory MR, and multi-detector row CT cholangiography- initial experience. Radiology 2004;230:645-651.
22. Alvaro D, Alpini G, Onori P, et al. Effect of ovariectomy on the proliferative capacity of intrahepatic rat cholangiocytes. Gastroenterology 2002;123:336-344.
23. Reagan-Shaw S, Nihal M, Ahmad N. Dose translation from animal to human studies revisited. FASEB J 2008;22:659-661.
24. Dalal PU, Howlett DC, Sallomi DF, et al. Does intravenous glucagon improve common bile duct visualisation during magnetic resonance cholangiopancreatography? Results in 42 patients. Eur J Radiol 2004;49:258-261.
25. Gong AY, Masyuk AI, Splinter PL, et al. Channel-mediated water movement across enclosed or perfused mouse intrahepatic bile duct units. Am J Physiol Cell Physiol 2002;283:C338-C346.
26. Tabibian JH, Asham EH, Han S, et al. Endoscopic treatment of postorthotopic liver transplantation anastomotic biliary strictures with maximal stent therapy (with video). Gastrointest Endosc 2010;71:505-512.
27. Witczak-Malinowska K, Gorycki T, Stalke P, et al. Value of magnetic resonance cholangiography (MRC) in primary sclerosing cholangitis (PSC). Med Sci Monit 2001;7(Suppl 1):114-117.
28. MacCarty RL, LaRusso NF, Wiesner RH, et al. Primary sclerosing cholangitis: findings on cholangiography and pancreatography. Radiology 1983;149:39-44.
29. van Nieuwerk CM, Groen AK, Ottenhoff R, et al. The role of bile salt composition in liver pathology of mdr2 (-/-) mice: differences between males and females. J Hepatol 1997;26:138-145.
30. Masyuk TV, Radtke BN, Stroope AJ, et al. Inhibition of Cdc25A suppresses hepato-renal cystogenesis in rodent models of polycystic kidney and liver disease. Gastroenterology 2012;142:622-633.e4.
31. O'Hara SP, Splinter PL, Trussoni CE, et al. Cholangiocyte N-Ras protein mediates lipopolysaccharide-induced interleukin 6 secretion and proliferation. J Biol Chem 2011;286:30352-30360.
32. Vierling JM, Hreha G, Wang H, et al. The role of biliary epithelial cells in the immunopathogenesis of non-suppurative destructive cholangitis in murine hepatic graft-versus-host disease. Trans Am Clin Climatol Assoc 2011;122:326-335.
33. Figueiredo JL, Siegel C, Nahrendorf M, et al. Intraoperative nearinfrared fluorescent cholangiography (NIRFC) in mouse models of bile duct injury. World J Surg 2010;34:336-343.
34. Sparks EE, Huppert KA, Brown MA, et al. Notch signaling regulates formation of the three-dimensional architecture of intrahepatic bile ducts in mice. Hepatology 2010;51:1391-1400.
35. Masyuk TV, Ritman EL, LaRusso NF. Quantitative assessment of the rat intrahepatic biliary system by three-dimensional reconstruction. Am J Pathol 2001;158:2079-2088.
36. Zhang X, Yang XR, Chen Y, et al. Diffraction-enhanced radiography of various mouse organs. Am J Roentgenol 2010;195:545-549.